Clinical trial Recruiting at 1 site Observational Ages 18 and up

Collecting biological samples from individuals with and without lung disease

Official title: Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Run by Weill Medical College of Cornell University · NCT01776398 · Data updated 2026-11-12

This study is collecting blood, urine, and airway samples from both healthy people and those with lung diseases to see how their biology differs and learn more about these conditions.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2000 (estimated)
SponsorWeill Medical College of Cornell University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedAugust 29, 2012
Main results expectedDecember 2027
Study endsDecember 2028
Registry record updatedOctober 23, 2026
Trial IDNCT01776398 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older, both healthy volunteers and individuals diagnosed with lung diseases.

Probably not a fit

Patients who are not able to provide informed consent or are under 18 years old may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather blood, urine, and airway specimens from both healthy individuals and those diagnosed with various lung diseases, including COPD and idiopathic pulmonary fibrosis. The collected samples will be used to analyze genetic expression and other biological markers to better understand the causes and progression of lung diseases. By comparing samples from healthy controls to those with lung conditions, researchers hope to establish normal ranges for various parameters and gain insights into the pathogenesis of these diseases. The study employs techniques such as bronchoscopy to obtain airway cells for further analysis.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with lung diseases.

How similar studies have gone: Other studies have successfully utilized similar approaches to investigate lung diseases, suggesting a promising avenue for research.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Group 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS (Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):

* All study subjects should be able to provide informed consent
* Males or females ages 18 years and older
* Must provide HIV informed consent

Group 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE (As defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population. Smoking status is defined for individuals that may use any of the following: cigarettes, pipes, E-cigarettes, waterpipe, shisha, etc.):

* Must provide informed consent
* Males and females age 18 years and older
* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and/or (6) diseases of organs with known association with lung disease
* Must provide HIV informed consent

Additional Inclusion criteria for CF subjects:

• All CF subjects will be homozygous for the ΔF508 mutation, with mild-moderate lung disease as defined by FEV1 ≥ 50%

Group 2 - WCMC/NYPH CLINICAL PATIENTS

* Must provide informed consent
* Males and females, age 18 years and older
* Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) diseases of organs with known association with lung disease, and (7) individuals with the blood eosinophil levels of 5% or greater.

Group 3 - PCNY CLINICAL PATIENTS VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE

* Must provide informed consent
* Males and females, age 18 years and older
* Lung disease proven by at least one of the following: symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease

Exclusion Criteria:

Group 1.1 - HEALTHY VOLUNTEER RESEARCH SUBJECTS

* Individuals not deemed in good overall health by the investigator during screening visits and/or prior to the bronchoscopy will not be accepted into the study.
* Individuals with history of chronic lung disease, including asthma or with recurrent or recent (within three months) acute pulmonary disease will not be accepted into the study.
* Individuals with allergies to atropine or any local anesthetic will not be accepted into the study.
* Individuals with allergies to pilocarpine, isoproterenol, terbutaline, atropine or aminophylline will not be accepted into the study.
* Females who are pregnant or nursing will not be accepted into the study

Group 1.2 - VOLUNTEER RESEARCH SUBJECTS WITH LUNG DISEASE

* Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study
* Individuals deemed unable to complete the bronchoscopy due to health concerns by the investigator.
* Females who are pregnant or nursing

Additional Exclusion criteria for CF subjects:

* Experienced a recent (≤ 8 weeks) pulmonary exacerbation of their disease

Group 2 - WCMC/NYPH CLINICAL PATIENTS

* Patient refuses consent

Group 3 - PCNY CLINICAL PATIENTS

* Patient refuses consent

Where it's running

  • Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
    New York, New York, United States
    Recruiting

Study contacts

  • Principal investigator: Ronald G. Crystal, M.D. — Weill Medical College of Cornell University
  • Study coordinator: Niamh Savage
  • Email: nis2049@med.cornell.edu
  • Phone: 12127460284

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.